Original title: Litfulo▼ (ritlecitinib): obvestilo za zdravstvene delavce
The Slovenian medicines agency (JAZMP) has published a Direct Healthcare Professional Communication about updated recommendations for Litfulo (ritlecitinib) to mitigate risks of major cardiovascular adverse events, malignancies, venous thromboembolism, serious infections, and mortality. Healthcare professionals are informed that the communication is available on the JAZMP website.
Zdravstvene delavce obveščamo, da je na spletni strani JAZMP objavljeno neposredno obvestilo (angl. DHPC – Direct Healthcare Professional Communication) o posodobljenih priporočilih za zmanjšanje tveganj za pomembne srčno-žilne neželene dogodke, maligne bolezni, vensko trombembolijo, resne okužbe in umrljivost pri uporabi zdravila Litfulo. Obvestilo je dostopno na naslednji povezavi.
Excerpt from the official page. The original is authoritative.